Lixte Biotechnology (NMAD) Stock Price, News & Analysis

Company Overview

Lixte Biotechnology Holdings, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, survival and response to treatment. The company’s research is based on the premise that inhibiting PP2A may help make cancer cells more vulnerable to existing therapies.

Lixte’s lead investigational compound is LB-100, a small-molecule PP2A inhibitor being evaluated in combination with other cancer treatments. The company has explored LB-100 in preclinical studies and early-stage clinical trials involving solid tumors and other malignancies. Lixte’s development strategy centers on combining its PP2A-targeting compounds with chemotherapy, radiation, immunotherapy or other targeted treatments.

Founded in 2001, Lixte is headquartered in Pasadena, California. As a clinical-stage company, it focuses primarily on research and development and does not have an established commercial product portfolio. Its programs are directed toward potential applications in oncology, although the safety and effectiveness of its investigational treatments remain subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $3.56 to $3.86
• 50-Day Range: $3.27 to $7.51
• 52-Week Range: $2.36 to $8.38
• Volume: 194,756 shs
• Average Volume: 215,956 shs
• Market Capitalization: $57.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lixte Biotechnology Stock Analysis - MarketRank™

Lixte Biotechnology scored higher than 14% of companies evaluated by MarketBeat, and ranked 622nd out of 671 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Lixte Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lixte Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lixte Biotechnology is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lixte Biotechnology is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lixte Biotechnology has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.50% of the float of Lixte Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Lixte Biotechnology has a short interest ratio ("days to cover") of 3.75, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lixte Biotechnology has recently decreased by 6.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lixte Biotechnology does not currently pay a dividend.

Dividend Growth

Lixte Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.98

News Sentiment

Lixte Biotechnology has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Industrials companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lixte Biotechnology this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Lixte Biotechnology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.30% of the stock of Lixte Biotechnology is held by insiders.

Percentage Held by Institutions

5.10% of the stock of Lixte Biotechnology is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: Electrical Equipment
• Sub-Industry: Electrical Components & Equipment
• Current Symbol: NASDAQ:NMAD
• Previous Symbol: NASDAQ:LIXT
• CIK: 1335105
• Web: www.lixte.com
• Phone: (631) 830-7092
• Fax: 631-982-5050
• Employees: 4
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -75.49%
• Return on Assets: -62.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.87
• Quick Ratio: 12.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 3.41

Miscellaneous

• Outstanding Shares: 16,100,000
• Free Float: 14,926,000
• Market Cap: $57.64 million
• Optionable: Not Optionable
• Beta: 1.30